MicroRNA-876 is sponged by long noncoding RNA LINC00707 and directly targets metadherin to inhibit breast cancer malignancy
Authors Li T, Li Y, Sun H
Received 1 April 2019
Accepted for publication 6 May 2019
Published 6 June 2019 Volume 2019:11 Pages 5255—5269
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Tong Li,1 Yunpeng Li,2 Hongyan Sun1
1Department of General Surgery, The Fourth People’s Hospital of Jinan, Jinan, Shandong 250031, People’s Republic of China; 2Department of General Surgery, Ningjin County People’s Hospital, Ningjin, Shandong 253400, People’s Republic of China
Background: MicroRNA-876-5p (miR-876) dysregulation contributes to the aggressiveness of various types of human cancer. This study was aimed at measuring miR-876 expression in breast cancer, determining the specific roles of miR-876 in the progression of breast cancer and understanding the corresponding molecular mechanisms.
Materials and methods: miR-876 expression in breast cancer tissues and cell lines was quantified via RT-qPCR. The effect of miR-876 upregulation on the malignant phenotype of breast cancer cells was investigated using CCK-8 assays, flow cytometry, Transwell migration and invasion assays and tumor xenograft experiments. The mechanisms underlying the tumor-suppressive action of miR-876 in breast cancer cells were explored using bioinformatic analysis, luciferase reporter assays, RT-qPCR and Western blot analysis.
Results: miR-876 was found to be underexpressed in breast cancer tissues and cell lines. Decreased miR-876 expression notably correlated with lymphatic invasion metastasis, TNM stage and differentiation grade. Overall survival was lower among patients with breast cancer and low miR-876 expression than in patients with high miR-876 expression. Restoration of miR-876 expression decreased breast cancer cell proliferation, migration and invasion in vitro and restricted tumor growth in vivo as well as increased cell apoptosis. Metadherin (MTDH) was identified as a novel target of miR-876 in breast cancer cells. Furthermore, long intergenic nonprotein-coding RNA 707 (LINC00707) acted as a molecular sponge for miR-876, thereby regulating MTDH expression in breast cancer. Finally, silencing miR-876 expression attenuated the influence of a LINC00707 knockdown on the malignancy of breast cancer cells.
Conclusion: This study, thus, revealed the vital functions of the LINC00707–miR-876–MTDH pathway in breast cancer and provided attractive targets and markers for its treatment.
Keywords: breast cancer, microRNA-876-5p, metadherin, long intergenic non-protein-coding RNA 707, therapeutic target
Breast cancer, which is derived from mammary epithelial tissue, is one of the most prevalent human malignant tumors among women worldwide.1 Morbidity and mortality among patients with breast cancer in China accounts for approximately 12.2% and 9.6% of global figures, respectively.2–4 In the past few decades, considerable advances in the diagnosis and treatment have led to an obvious improvement in the clinical outcomes of patients with breast cancer. Unfortunately, to date, breast cancer is still a refractory disease, mainly owing to its recurrence, metastasis and tolerance to radiotherapy and chemotherapy.5–7 Multiple factors, including the activation of oncogenes, deactivation of tumor suppressors and other hereditary and epigenetic alterations, are involved in the initiation and progression of breast cancer.8–10 However, details of the underlying mechanisms regulating breast cancer progression are not yet fully understood. Thus, a comprehensive understanding of the molecular mechanisms underlying breast cancer pathogenesis is crucial for the identification of novel targets for precision therapy.
MicroRNAs (miRNAs) are a group of evolutionarily conserved, noncoding and short RNA molecules 19–24 nucleotides long.11 miRNAs act as gene expression regulators by imperfect or near-perfect base pairing with the 3′-UTRs of their target mRNAs, thereby resulting in translation suppression and/or mRNA degradation.12 Multiple lines of evidence have demonstrated that nearly all cellular physiological and pathological processes are closely regulated by miRNAs including carcinogenesis and cancer progression.13–15 The aberrant expression of miRNAs is a common and important feature of breast cancer, and their dysregulation participates in the malignant phenotypes of breast cancer by acting as oncogenes or tumor suppressors.16–18 Therefore, silencing of oncogenic miRNAs and restoring the expression of tumor-suppressing miRNAs might be a promising therapeutic method for patients with breast cancer.
Long noncoding RNAs (lncRNAs) are another group of noncoding RNA transcripts that are implicated in the regulation of various pathological processes, by performing important functions in the malignant progression of human cancers.19 It is well-known that lncRNAs are able to serve as competing endogenous RNAs (ceRNAs) to modulate the expression of genes by sponging miRNAs, thus titrating available miRNAs and contributing to tumorigenesis, including breast carcinogenesis.20–22 Accordingly, further exploration of the specific functions of lncRNAs in breast cancer is likely to provide effective targets for the development of therapies.
Abnormal expression of miR-876-5p (miR-876) contributes to the aggressiveness of multiple types of human cancer, including osteosarcoma,23 hepatocellular carcinoma,24 lung cancer,25 and head and neck squamous cell carcinoma.26 However, whether miR-876 is aberrantly expressed in breast cancer and its mechanisms of action have not yet been investigated. In this article, we provided experimental evidence that miR-876 is sponged by LINC00707 and can restrain breast cancer progression through metadherin (MTDH) downregulation.
Materials and methods
The Ethics Committee of The Fourth People’s Hospital of Jinan approved the study protocol, and written informed consent was provided by all individual participants prior to surgical resection. All the experimental procedures were in accordance with the Declaration of Helsinki.
Tissues and cell lines
In total, 53 pairs of breast cancer samples and adjacent normal tissues were collected from breast cancer patients at The Fourth People’s Hospital of Jinan who had not been treated with any preoperative therapies, such as radiotherapy or chemotherapy. The tissue samples were snap-frozen in liquid nitrogen after surgical excision and stored at −80°C until total RNA and protein isolation.
The four breast cancer cell lines, MCF-7, MDA-MB-231, BT-474 and SKBR3, and human breast epithelial cell line MCF-10A were purchased from the Chinese Academy of Sciences (Shanghai, China). All the cell lines were kept at 37°C in a humidified chamber with 5% CO2 and were grown in DMEM containing 10% FBS and 1% penicillin–streptomycin mixture (all from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA).
The miR-876 agomir (agomir-876), negative control agomir (agomir-NC), miR-876 antagomir (antagomir-876) and antagomir-NC were acquired from Shanghai GenePharma Co., Ltd. (Shanghai, China). The small interfering RNA (siRNA) targeting LINC00707 (si-LINC00707) and the negative control siRNA (si-NC) were chemically synthesized by Guangzhou RiboBio Co. Ltd. (Guangzhou, China). The MTDH sequence lacking its 3′-UTR was produced by Guangzhou RiboBio Co. Ltd., inserted into the pcDNA3.1 plasmid, and the resulting plasmid was named pcDNA3.1-MTDH (pc-MTDH). Cells were seeded in 6-well plates 24 hrs prior to transfection. Transient transfection was performed using Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.), as per the manufacturer’s protocol.
RNA isolation and RT-qPCR
Total RNA was isolated with TRIzol® Reagent (Thermo Fisher Scientific, Inc.), and the concentration and quality were determined using a Nanodrop® ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc). miR-876 expression was determined by means of the Mir-X™ miRNA qRT-PCR TB Green™ Kit (Takara Biotechnology Co., Ltd., Dalian, China) with small nuclear RNA U6 as the control. MTDH mRNA and LINC00707 expression were quantified by reverse transcription and qPCR with the PrimeScript® RT reagent kit (Takara Biotechnology Co.) and SYBR® Premix Ex Taq™ II Kit (Takara Biotechnology Co.), respectively. Relative MTDH mRNA and LINC00707 expression levels were normalized to GAPDH. The 2−ΔΔCq method was used to analyze relative gene expression.27
Cell counting kit-8 (CCK-8) assay
Transfected cells were collected and separately seeded in 96-well microtiter plates (Corning Incorporated, Corning, NY, USA) at a density of 3×103 cells per well. The CCK-8 assay was performed to evaluate cell proliferation at 4 consecutive time points: 0, 24, 48 and 72 hrs after seeding. Briefly, 10 μL of the CCK-8 reagent (Dojindo, Gaithersburg, MD) was added into each well and the cells were incubated at 37°C and 5% CO2 for another 2 hrs. Absorption at a 450 nm wavelength was measured on a microplate reader (Bio-Rad, Hercules, CA, USA).
Flow cytometric analysis of apoptosis
After 48 hrs culture, the transfected cells were harvested, washed three times with ice-cold PBS and analyzed for cell apoptosis using the Annexin V-FITC Apoptosis Detection Kit (BioLegend, San Diego, CA, USA). In particular, the transfected cells were resuspended in 100 µL binding buffer supplemented with 5 µL Annexin V-FITC and 5 µL propidium iodide. Following 30-min incubation at room temperature in the dark, the prevalence of apoptosis was determined using a flow cytometer (FACScan, BD Biosciences, Heidelberg, Germany). CellQuest software (BD Biosciences, Heidelberg, Germany) was employed to analyze the data.
Transwell migration and invasion assays
Migration and invasion were examined using a 24-well Transwell chamber (Corning Costar, Corning, NY, USA) containing a polycarbonate membrane filter (pore size: 8 μm). Matrigel (BD Biosciences, Franklin Lakes, NJ, USA)-coated chambers were used for the invasion assay, while the chambers in the migration assay were not coated with Matrigel. For both assays, a total of 5×104 transfected cells were seeded in the upper chambers. The bottom chambers were filled with 500 μL DMEM containing 10% FBS. The cells were incubated at 37°C and 5% CO2 for 24 hrs. The nonmigratory and noninvading cells were gently removed with a cotton swab, whereas the migratory and invading cells were fixed in 70% ethanol, stained with 0.1% crystal violet and photographed under an inverted light microscope (Olympus Corporation, Tokyo, Japan). Finally, the migratory or invading cells in five randomly selected visual fields were counted.
Tumor xenograft experiments
The procedures for all animal experiments were approved by the Animal Research Committee of The Fourth People’s Hospital of Jinan and were conducted in accordance with the Animal Protection Law of the People’s Republic of China-2009 for experimental animals. MCF-7 cells transfected with agomir-876 or agomir-NC were harvested 24 hrs post-transfection and implanted into the dorsal flank of nude mice that were purchased from Vital River Laboratory Animal Technology (Beijing, China). The agomir-876 group was injected with miR-876–overexpressing cells, whereas the agomir-NC group was injected with agomir-NC–expressing cells. Four weeks following the cell injection, all the nude mice were euthanized under anesthesia, and the tumor weights and volumes were measured. Tumor volume was calculated using the following formula: tumor volume = (width2× length)/2.
Three miRNA target prediction bioinformatics tools, TargetScan (
StarBase 3.0 (
A luciferase reporter assay
The 3′-UTR fragments of MTDH containing the wild-type (WT) or mutant (MUT) miR-876–binding site were amplified by Shanghai GenePharma Co. Ltd. and cloned into the psiCHECK2 vector (Promega Corporation, Madison, WI, USA). These luciferase reporter plasmids were designated as MTDH-WT and MTDH-MUT, respectively. LINC00707-WT and LINC00707-MUT reporter plasmids were also produced by Shanghai GenePharma Co. Ltd. Cells were seeded in 24-well plates and co-transfected with the luciferase reporter plasmids and agomir-876 or agomir-NC by means of Lipofectamine® 2000. Finally, the cells were collected, and luciferase activity was detected using the Dual Luciferase Reporter Assay (Promega Corporation, Madison, WI, USA). Firefly luciferase activity was normalized to Renilla luciferase activity.
Cell lysates were prepared using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China). The total protein concentration was measured using the BCA Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc.). Equivalent amounts of protein were resolved by SDS-PAGEin a 10% gel, transferred onto polyvinylidene difluoride membranes and blocked at room temperature with a 5% nonfat milk solution. After incubation overnight at 4 °C with primary antibodies against MTDH (cat. # ab227981; Abcam; Cambridge, MA, USA) or GAPDH (cat. # ab128915; Abcam), the membranes were probed with a goat anti-rabbit IgG horseradish peroxidase–conjugated secondary antibody (cat. # ab6721; Abcam) at room temperature for 1 hr. Finally, an enhanced chemiluminescence detection system (ECL; Bio-Rad Laboratories, Inc.) was employed to visualize the protein signals.
Each experiment was repeated at least three times. All data are expressed as mean ± SD and were analyzed in the SPSS software, version 16 (SPSS, Inc., Chicago, IL, USA). Pearson’s χ2 test was conducted to determine the association between miR-876 and clinical characteristics among patients with breast cancer. Correlation between miR-876 and MTDH as well as LINC00707 expression in the same breast cancer tissues was examined via Spearman’s correlation analysis. The Kaplan–Meier method along with the log-rank test was applied to assess the prognostic value of miR-876 in patients with breast cancer. P<0.05 was assumed to indicate a statistically significant difference.
Expression profile of miR-876 in breast cancer and its associations with clinical factors
To obtain an overview of the expression profile of miR-876, we first measured its expression in 53 pairs of breast cancer samples and adjacent normal tissues. An obvious decrease in miR-876 expression was identified in breast cancer tissue samples compared with that in adjacent normal tissue samples (Figure 1A, P<0.05). Similarly, the expression of miR-876 was significantly lower in MCF-7, MDA-MB-231, BT-474 and SKBR3 cell lines than in human breast epithelial cell line MCF-10A, especially in the MCF-7 and MDA-MB-231 cell lines (Figure 1B, P<0.05). Therefore, the two cell lines were chosen for further experiments.
We next investigated whether miR-876 expression in breast cancer tissues correlated with clinical factors. All breast cancer patients were classified into either low– or high–miR-876 expression groups, based on the median miR-876 expression level in breast cancer tissues. There was no significant correlation between miR-876 expression and age (P=0.158), or tumor size (P=0.412) of patients with breast cancer. However, a significant correlation was observed between decreased miR-876 expression and lymphatic invasion metastasis (P=0.002), TNM stage (P=0.034) and differentiation grade (P=0.029; Table 1). We also analyzed the overall survival rate of breast cancer patients with low or high miR-876 expression levels. The results revealed that patients with breast cancer and low miR-876 expression had shorter overall survival than patients with relatively high levels of miR-876 expression (Figure 1C, P=0.012). These observations suggested that aberrant expression of miR-876 may be closely related to the initiation and progression of breast cancer.
Table 1 The association between miR-876 and clinical characteristics among patients with breast cancer
miR-876 upregulation inhibits breast cancer cell growth and metastasis in vitro
To manipulate the expression of miR-876 in breast cancer cells, synthetic agomir-876 was introduced into MCF-7 and MDA-MB-231 cells. RT-qPCR analysis clearly confirmed that miR-876 was effectively upregulated in MCF-7 and MDA-MB-231 cells after agomir-876 transfection (Figure 2A, P<0.05). A CCK-8 assay for cellular proliferation showed that ectopic miR-876 expression notably decreased the proliferation of MCF-7 and MDA-MB-231 cells (Figure 2B, P<0.05). The influence of miR-876 overexpression on breast cancer cell apoptosis was next examined via flow cytometric analysis. As presented in Figure 2C, the proportion of apoptotic cells increased when miR-876 was overexpressed in MCF-7 and MDA-MB-231 cells (P<0.05). Furthermore, Transwell migration and invasion assays indicated that agomir-876 transfection led to obvious reductions in MCF-7 and MDA-MB-231 cell migration and invasion (Figure 2D and E, P<0.05). These results collectively meant that miR-876 functions as a tumor-suppressing miRNA in breast cancer.
MTDH is a direct target of miR-876 in breast cancer cells
As for the mechanism, miRNAs are known to regulate the expression of their targets.12 Accordingly, identifying the direct target gene of miR-876 in breast cancer cells was essential for understanding its role in the aggressiveness of breast cancer. Bioinformatics analysis predicted that the 3′-UTR of MTDH mRNA contains a complementary binding site for miR-876 (Figure 3A). The luciferase reporter assay was conducted to determine whether MTDH mRNA was a direct target of miR-876 in breast cancer. The results revealed that transfection of agomir-876 significantly reduced the luciferase activity of MTDH-WT in MCF-7 and MDA-MB-231 cells (P<0.05), whereas cotransfection of agomir-876 and MTDH-MUT did not affect luciferase activity (Figure 3B and C).
We next evaluated the potential association between miR-876 and MTDH in breast cancer. RT-qPCR analysis indicated that MTDH mRNA expression was higher in breast cancer tissue samples than in adjacent normal tissues (Figure 3D, P<0.05). Notably, an inverse correlation was observed between miR-876 and MTDH mRNA in breast cancer tissue samples, as demonstrated by Spearman’s correlation analysis (Figure 3E; R2=0.3348, P<0.0001). Furthermore, compared with cells transfected with agomir-NC, MTDH expression was suppressed at both mRNA (Figure 3F, P<0.05) and protein levels (Figure 3G, P<0.05) in MCF-7 and MDA-MB-231 cells when transfected with agomir-876. These results meant that MTDH mRNA is a direct target of miR-876 in breast cancer.
Restoring MTDH expression reduces miR-876–mediated inhibition of breast cancer cell growth and metastasis in vitro
To test whether MTDH is involved in miR-876’s tumor-suppressive effects in breast cancer, we restored MTDH expression in miR-876–overexpressing MCF-7 and MDA-MB-231 cells by cotransfection with the MTDH overexpression plasmid pc-MTDH. Unsurprisingly, upregulation of miR-876 noticeably decreased MTDH protein expression in MCF-7 and MDA-MB-231 cells. By contrast, the decreased MTDH expression due to agomir-876 transfection was attenuated in the two cell lines cotransfected with pc-MTDH (Figure 4A, P<0.05). Functionally, restoration of MTDH expression abrogated the decrease in cell proliferation (Figure 4B, P<0.05) and the increase in apoptosis (Figure 4C, P<0.05) induced by miR-876 overexpression in MCF-7 and MDA-MB-231 cells. Furthermore, the decrease in cell migration (Figure 4D, P<0.05) and invasion (Figure 4E, P<0.05) caused by agomir-876 transfection was attenuated by restoration of MTDH expression. These results suggested that miR-876 exerts its anticancer activity in breast cancer by decreasing MTDH expression.
LncRNA LINC00707 acts as a sponge for miR-876 in breast cancer cells
It is well-known that lncRNA can act as a molecular sponge binding miRNAs and thereby titrating free miRNA.19 Thus, we hypothesized that miR-876 is sponged by some lncRNA, resulting in the restriction of breast cancer progression. To test this hypothesis, bioinformatics analysis was performed and two potential miR-876–binding sites in LINC00707 were identified (Figure 5A). The luciferase reporter assay was then carried out to confirm that miR-876 is a downstream target of LINC00707 in breast cancer cells. It was observed that miR-876 overexpression significantly suppressed the luciferase activity of LINC00707-WT (both 1 and 2) in MCF-7 and MDA-MB-231 cells (Figure 5B; P<0.05). However, transfection with agomir-876 failed to affect the luciferase activity of LINC00707-MUT (both 1 and 2).
RT-qPCR analysis confirmed that LINC00707 expression was higher in breast cancer tissue samples than in adjacent normal tissue samples (Figure 5C, P<0.05). Importantly, LINC00707 expression negatively correlated with miR-876 expression in the same breast cancer tissue (Figure 5D; R2=0.3697, P<0.0001). In addition, si-LINC00707–mediated silencing of LINC00707 expression (Figure 5E, P<0.05) significantly increased miR-876 expression (Figure 5F, P<0.05). Furthermore, Western blotting revealed that in MCF-7 and MDA-MB-231 cells, transfection with si-LINC00707 significantly downregulated MTDH protein (Figure 5G, P<0.05). Taken together, these results confirmed that LINC00707 acts as a molecular sponge for miR-876 to regulate MTDH expression in breast cancer.
LINC00707 knockdown inhibits the proliferation, migration and invasiveness and induces the apoptosis of breast cancer cells
To explore the specific roles of LINC00707 in breast cancer, si-LINC00707 was transfected to silence LINC00707 expression in MCF-7 and MDA-MB-231 cells. si-NC acted as the control for si-LINC00707. Predictably, the LINC00707 knockdown significantly decreased the proliferation of MCF-7 and MDA-MB-231 cells (Figure 6A, P<0.05). In addition, LINC00707-depleted MCF-7 and MDA-MB-231 cells showed significantly more apoptosis (Figure 6B, P<0.05). Furthermore, Transwell migration and invasion assays indicated that the number of cells that migrated (Figure 6C, P<0.05) and invaded (Figure 6D, P<0.05) was lower in the si-LINC00707 group than in the si-NC group. These findings confirmed that LINC00707 has tumor-promoting effects on the growth and metastasis of breast cancer in vitro.
miR-876 is responsible for the tumor-promoting functions of LINC00707 in breast cancer cells
To determine whether the effects of LINC00707 silencing in breast cancer cells were mediated by miR-876, MCF-7 and MDA-MB-231 cells were cotransfected with si-LINC00707 and antagomir-876 or antagomir-NC; then cell proliferation, apoptosis, migration and invasion were examined by CCK-8, flow cytometric and Transwell migration and invasion assays, respectively. The increased miR-876 expression (Figure 7A, P<0.05) and decreased MTDH protein expression (Figure 7B, P<0.05) in the LINC00707 knockdown MCF-7 and MDA-MB-231 cells were reversed by cotransfection with antagomir-876, as revealed by RT-PCR and Western blotting. Functional experiments revealed that the loss of LINC00707 significantly inhibited cell proliferation (Figure 7C, P<0.05), induced apoptosis (Figure 7D, P<0.05) and decreased migration (Figure 7E, P<0.05) and invasiveness (Figure 7F, P<0.05) in MCF-7 and MDA-MB-231 cells. However, cotransfection with antagomir-876 abrogated these effects of LINC00707 silencing. In summary, these results suggested that LINC00707 is implicated in the regulation of breast cancer progression by regulating miR-876 activity.
MiR-876 upregulation decreases tumor growth of breast cancer cells in vivo
Tumor xenograft experiments were conducted to examine the function of miR-876 overexpression in breast cancer tumor growth in vivo. The volumes (Figure 8A and B, P<0.05) and weights (Figure 8C, P<0.05) of tumor xenografts were both smaller in the agomir-876 group than in the agomir-NC group. In addition, RT-qPCR analysis showed that miR-876 expression in tumor xenografts from the agomir-876 group was higher than that in the agomir-NC group (Figure 8D, P<0.05). Then, we measured the MTDH protein levels in the formed tumor xenografts. MTDH protein expression was also downregulated in vivo after miR-876 upregulation (Figure 8E, P<0.05). These results suggested that miR-876 exerts an inhibitory action on the tumor growth of breast cancer cells in vivo.
In recent years, aberrant miRNA expression has been identified in breast cancer, which has important roles in the progression of malignancy.28 miRNAs can act as tumor suppressors or oncogenic molecules depending on the biological functions of their targets.29 Therefore, exploring the functions of cancer-specific miRNAs in breast cancer and their mechanisms of action is needed to identify effective targets for anticancer therapy. In this study, for the first time, we measured the expression of miR-876 in breast cancer and evaluated its clinical value. In addition, the detailed roles of miR-876 in the progression of breast cancer were explored using a series of experiments. Notably, another aim of this study was to determine the mechanisms underlying the activity of miR-876 in breast cancer progression, which might be helpful for identifying promising targets for novel treatments.
miR-876 is downregulated in osteosarcoma, and its downregulation positively correlates with an advanced clinical stage and poor differentiation status.23 Patients with osteosarcomas that have low miR-876 expression exhibit worse overall survival than patients with high miR-876 expression.23 miR-876 is also expressed at low levels in hepatocellular carcinoma,24 lung cancer,25 and head and neck squamous cell carcinoma.26 Nevertheless, to date, few studies have focused on the expression profile of miR-876 in breast cancer. Here, we found that miR-876 expression is low in breast cancer tissues and cell lines. Low miR-876 expression correlated with lymphatic invasion metastasis, TNM stage and differentiation grade. More importantly, patients with breast cancer containing low levels of miR-876 showed lower overall survival than patients with high levels of miR-876 expression. These observations suggest that miR-876 might be an effective diagnostic and prognostic biomarker for patients with breast cancer.
miR-876 has tumor-suppressive roles in the carcinogenesis and cancer progression. For instance, miR-876 upregulation restricts osteosarcomas cell proliferation, migration and invasion in vitro and hinders tumor growth in vivo.23 Ectopic miR-876 expression suppresses cell metastasis in head and neck squamous cell carcinoma both in vitro and in vivo.26 Furthermore, miR-876 has been validated as a tumor-suppressing miRNA in hepatocellular carcinoma24 and lung cancer.25 However, whether miR-876 is involved in breast cancer progression has remained unknown until now. In this study, restoring miR-876 expression decreased the proliferation, migration and invasion of breast cancer cells in vitro and promoted cell apoptosis. In addition, miR-876 overexpression dramatically delayed the growth of breast cancer-derived tumors in vivo. Accordingly, miR-876 has potential as an effective target for breast cancer therapy.
Multiple genes, including c-Met in osteosarcoma,23 BCL6 corepressor-like 1,24 DNA (cytosine-5)-methyltransferase 3A30 in hepatocellular carcinoma and bone morphogenetic protein 4 in lung cancer,25 have been identified as direct target genes of miR-876. Currently, the lncRNA–miRNA–mRNA axis is the most typical regulatory mechanism for lncRNA. Here, MTDH mRNA was identified as a direct target of miR-876 in breast cancer cells, with LINC00707 acting as a ceRNA for miR-876 to regulate MTDH expression. MTDH is upregulated in breast cancer and its overexpression is related to nuclear grade, negative estrogen receptor and progesterone receptor expression, disease-free survival, distant-metastasis-free survival and overall survival.31 Multivariate analysis identified MTDH as an independent biomarker of poor disease-free survival and distant metastasis–free survival rates.31 MTDH functions in many biological processes closely related to breast cancer formation and progression.32–35 Therefore, MTDH silencing due to miR-876 overexpression might be an attractive therapeutic technique in patients with breast cancer.
LINC00707 expression is high in lung adenocarcinomas, and its upregulation is associated with advanced TNM stage, larger tumor size, lymphatic metastasis and poor prognosis.36 LINC00707 is upregulated in gastric cancer, and this increase correlates with tumor stage, tumor size, lymph node metastasis and worsened prognosis.37 Several studies have shown that LINC00707 is a key regulatory lncRNA in lung adenocarcinomas,36 gastric cancer37 and hepatocellular carcinoma.38,39 These tumor-promoting actions work through multiple mechanisms, including downregulation of Cdc42 in lung adenocarcinomas,36 interaction with mRNA-stabilizing protein HuR in gastric cancer37 and activation of the ERK–JNK–AKT pathway38 and sponging miR-20639 in hepatocellular carcinoma. Herein, we demonstrated the upregulation of LINC00707 in breast cancer and evaluated its effect. LINC00707 promoted the oncogenicity of breast cancer cells through sponging miR-876 and subsequently regulating MTDH expression. Hence, LINC00707, miR-876 and MTDH may be interrelated and, thus, regulate the aggressiveness of breast cancer.
We proved that miR-876 is downregulated in breast cancer tissues and cell lines, and that its decreased expression is associated with poor prognosis among patients with breast cancer. This study also uncovered the role of the LINC00707–miR-876–MTDH pathway in the malignant progression of breast cancer and provided novel targets for the management of breast cancer. However, we did not explore the effect of miR-873 on the metastasis of breast cancer in vivo. It is a limitation of our study, and we will resolve it in our future investigation.
The authors report no conflicts of interest in this work.
1. Hamann U, Ankel C. [Breast cancer: diagnostics and therapy - the most important facts for internists]. Deutsche Medizinische Wochenschrift. 2018;143(4):267–278. doi:10.1055/s-0043-104456
2. Varghese F, Wong J. Breast cancer in the elderly. Surg Clin North Am. 2018;98(4):819–833. doi:10.1016/j.suc.2018.04.002
3. Kluthcovsky AC, Faria TN, Carneiro FH, Strona R. Female breast cancer mortality in Brazil and its regions. Rev Assoc Med Bras. 2014;60(4):387–393.
4. Lin X, Chen W, Wei F, Ying M, Wei W, Xie X. Night-shift work increases morbidity of breast cancer and all-cause mortality: a meta-analysis of 16 prospective cohort studies. Sleep Med. 2015;16(11):1381–1387. doi:10.1016/j.sleep.2015.02.543
5. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–1564. doi:10.1126/science.1203543
6. Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012;11(6):479–497. doi:10.1038/nrd2372
7. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–643. doi:10.1038/nrc2713
8. Raval GN, Bharadwaj S, Levine EA, et al. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene. 2003;22(40):6194–6203. doi:10.1038/sj.onc.1206719
9. Volinsky N, McCarthy CJ, von Kriegsheim A, et al. Signalling mechanisms regulating phenotypic changes in breast cancer cells. Biosci Rep. 2015;35(2). doi:10.1042/BSR20150111.
10. Sauter ER. Breast cancer prevention: current approaches and future directions. Eur J Breast Health. 2018;14(2):64–71. doi:10.5152/ejbh.2018.3978
11. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–269. doi:10.1038/nrc1840
12. Sempere LF, Keto J, Fabbri M. Exosomal microRNAs in breast cancer towards diagnostic and therapeutic applications. Cancers. 2017;9(7):71. doi:10.3390/cancers9070071
13. Delsin LEA, Salomao KB, Pezuk JA, Brassesco MS. Expression profiles and prognostic value of miRNAs in retinoblastoma. J Cancer Res Clin Oncol. 2019;145(1):1–10. doi:10.1007/s00432-018-2773-7
14. Link A, Kupcinskas J. MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: current insights and future perspectives. World J Gastroenterol. 2018;24(30):3313–3329. doi:10.3748/wjg.v24.i30.3313
15. To KK, Tong CW, Wu M, Cho WC. MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside. World J Gastroenterol. 2018;24(27):2949–2973. doi:10.3748/wjg.v24.i27.2949
16. Kong P, Chen L, Yu M, et al. miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer. Cell Death Dis. 2018;9(11):1059. doi:10.1038/s41419-018-1091-y
17. Zhang Y, Fang J, Zhao H, Yu Y, Cao X, Zhang B. Downregulation of microRNA-1469 promotes the development of breast cancer via targeting HOXA1 and activating PTEN/PI3K/AKT and Wnt/beta-catenin pathways. J Cell Biochem. 2019;120(4):5097–5107. doi:10.1002/jcb.27786
18. Li J, Lu M, Jin J, Lu X, Xu T, Jin S. miR-449a suppresses tamoxifen resistance in human breast cancer cells by targeting ADAM22. Cell Physiol Biochem. 2018;50(1):136–149. doi:10.1159/000493964
19. Quan M, Chen J, Zhang D. Exploring the secrets of long noncoding RNAs. Int J Mol Sci. 2015;16(3):5467–5496. doi:10.3390/ijms16035467
20. Jiao D, Li Z, Zhu M, Wang Y, Wu G, Han X. LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC). Am J Cancer Res. 2018;8(4):748–760.
21. Ma J, Fan Y, Feng T, et al. HOTAIR regulates HK2 expression by binding endogenous miR-125 and miR-143 in oesophageal squamous cell carcinoma progression. Oncotarget. 2017;8(49):86410–86422. doi:10.18632/oncotarget.21195
22. Li Y, Han X, Li Q, Wang C, Lou Z, Wang X. Long noncoding RNA HOXD-AS1 induces epithelial-mesenchymal transition in breast cancer by acting as a competing endogenous RNA of miR-421. J Cell Biochem. 2019;120(6):10633–10642.
23. Xie W, Xiao J, Wang T, Zhang D, Li Z. MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma. J Cell Mol Med. 2019;23:3293–3301. doi:10.1111/jcmm.2019.23.issue-5
24. Xu Q, Zhu Q, Zhou Z, et al. MicroRNA-876-5p inhibits epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by targeting BCL6 corepressor like 1. Biomed Pharmacother. 2018;103:645–652. doi:10.1016/j.biopha.2018.04.037
25. Bao L, Lv L, Feng J, et al. MiR-876-5p suppresses epithelial-mesenchymal transition of lung cancer by directly down-regulating bone morphogenetic protein 4. J Biosci. 2017;42(4):671–681.
26. Dong Y, Zheng Y, Wang C, et al. MiR-876-5p modulates head and neck squamous cell carcinoma metastasis and invasion by targeting vimentin. Cancer Cell Int. 2018;18:121. doi:10.1186/s12935-018-0619-7
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
28. Khordadmehr M, Shahbazi R, Ezzati H, Jigari-Asl F, Sadreddini S, Baradaran B. Key microRNAs in the biology of breast cancer; emerging evidence in the last decade. J Cell Physiol. 2019;234(6):8316–8326. doi:10.1002/jcp.27716
29. Mandujano-Tinoco EA, Garcia-Venzor A, Melendez-Zajgla J, Maldonado V. New emerging roles of microRNAs in breast cancer. Breast Cancer Res Treat. 2018;171(2):247–259. doi:10.1007/s10549-018-4850-7
30. Wang Y, Xie Y, Li X, et al. MiR-876-5p acts as an inhibitor in hepatocellular carcinoma progression by targeting DNMT3A. Pathol Res Pract. 2018. doi:10.1016/j.prp.2018.04.012
31. Tokunaga E, Nakashima Y, Yamashita N, et al. Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer. 2014;21(3):341–349. doi:10.1007/s12282-012-0398-2
32. Li J, Yang L, Song L, et al. Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1. Oncogene. 2009;28(36):3188–3196. doi:10.1038/onc.2009.171
33. Qian BJ, Yan F, Li N, et al. MTDH/AEG-1-based DNA vaccine suppresses lung metastasis and enhances chemosensitivity to doxorubicin in breast cancer. Cancer Immunol Immunother. 2011;60(6):883–893. doi:10.1007/s00262-011-0997-3
34. Li X, Kong X, Huo Q, et al. Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci. 2011;102(6):1151–1157. doi:10.1111/j.1349-7006.2011.01919.x
35. Wang C, Yang Q. Astrocyte elevated gene-1 and breast cancer (Review). Oncol Lett. 2011;2(3):399–405. doi:10.3892/ol.2011.268
36. Ma T, Ma H, Zou Z, et al. The long intergenic noncoding RNA 00707 promotes lung adenocarcinoma cell proliferation and migration by regulating Cdc42. Cell Physiol Biochem. 2018;45(4):1566–1580. doi:10.1159/000487693
37. Xie M, Ma T, Xue J, et al. The long intergenic non-protein coding RNA 707 promotes proliferation and metastasis of gastric cancer by interacting with mRNA stabilizing protein HuR. Cancer Lett. 2019;443:67–79. doi:10.1016/j.canlet.2018.11.032
38. Wang J, Luo Z, Yao T, Li W, Pu J. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway. J Cell Physiol. 2019;234(5):6908–6916. doi:10.1002/jcp.27449
39. Tu J, Zhao Z, Xu M, et al. LINC00707 contributes to hepatocellular carcinoma progression via sponging miR-206 to increase CDK14. J Cell Physiol. 2018;234(7):10615–10624.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]